Magdalena Kegel,  —

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

Articles by Magdalena Kegel

Oxygen Therapy Seen to Harm Lungs of Newborns with Pulmonary Hypertension

Oxygen therapy given newborns with persistent pulmonary hypertension likely works to cement the molecular changes that led to the condition in the first place, further worsening, rather than treating, the illness. The study, “Hypoxia and hyperoxia potentiate PAF receptor-mediated effects in newborn ovine pulmonary arterial smooth muscle cells: significance in oxygen…

Likelihood of PAH in Scleroderma Patients May Be Evident in Specific Autoantibodies

Researchers in Italy developed a clear way of exploring differences in autoantibodies to predict which scleroderma patients are likely to develop pulmonary arterial hypertension (PAH), improving their chances of getting appropriate treatment before changes in their lung blood vessels take place. The study, “Subspecificities of anticentromeric protein A antibodies identify…

2-Year Study of Riociguat as CTEPH Treatment Identifies Predictive Disease Markers

Recently published data from the CHEST-2 clinical trial showed that riociguat (Adempas) is both safe and effective as a longer term treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The study also identified two predictive biomarkers distinguishing CTEPH and pulmonary arterial hypertension (PAH), and their concentrations serve as prognostic guides of…

PAH Study Reveals Unexpected Genetic Complexity

Mutations in the ENG gene might contribute to disease mechanisms in pulmonary arterial hypertension (PAH), according to a recent study demonstrating that PAH patients often carry ENG gene changes in addition to other, more well-studied mutations. The study demonstrates that genetic contributions to PAH are more complex than anticipated, raising the…

Screening Rheumatoid Arthritis Patients for PAH May Be Relevant

Rheumatoid arthritis patients may be at greater risk for pulmonary arterial hypertension (PAH), and noninvasive screenings for PAH could identify the risk, offering a chance for treatment at early stages, according to recent findings from the University of Newcastle in Australia. The link between PAH and systemic sclerosis has long been accepted,…

PAH Progression Linked to MicroRNA, Offering Potential Drug Target

Researchers at England’s University of Sheffield have identified a microRNA that, when lacking in patients, appears to be driving the progression of pulmonary arterial hypertension (PAH). The findings, identifying potential new drug targets, open up avenues of research that might lead to better treatments for this fatal disease. “This research opens…